Company & Sponsor Intelligence
National Institute on Drug Abuse (NIDA)
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials6
Recruiting0
Completed4
Countries1
Therapeutic footprint
other_psychiatrysubstance_use
Indexed studies
NCT00000218Pharmacotherapy and Intensive Treatment - 2
substance_use · United StatesPHASE4
substance_use · United StatesPHASE4
NCT00249509Effectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals
substance_use · United StatesPHASE2
substance_use · United StatesPHASE2
NCT00015080Naltrexone in Treatment of Cocaine Dependence - 5
other_psychiatry · United StatesPHASE2
other_psychiatry · United StatesPHASE2
NCT00247689Methylphenidate Studies for Drug Abuse Vulnerability Molecular Genentics
substance_use · United StatesTERMINATED
substance_use · United StatesTERMINATED
NCT00124696Cocaethylene as a Treatment for Cocaine Dependence - 1
other_psychiatry · United StatesPHASE1
other_psychiatry · United StatesPHASE1
NCT00000340Pemoline in the Treatment of Stimulant Dependence - 5
other_psychiatry · PHASE2
other_psychiatry · PHASE2
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →